Safety, tolerability, pharmacokinetics, and pharmacodynamics of multiple doses of apixaban in healthy Japanese male subjects

International Journal of Clinical Pharmacology and Therapeutics

Volumn 52, Issue 7, 2014, Pages 564-573

  Yamahira, Naomi ^a   Frost, Charles ^b   Fukase, Hiroyuki ^c   Yu, Zhigang ^b   Wang, Jessie ^b   Pursley, Janice ^b   LaCreta, Frank ^b   Hiraoka, Masaki ^a  

^a Japanese Society of Clinical Pharmacology and Therapeutics   (Japan)

^b BRISTOL MYERS SQUIBB   (United States)

^c CPC Clinic   (Japan)

Author keywords

Apixaban; Japanese; Pharmacodynamics; Pharmacokinetics; Tolerability

Indexed keywords

APIXABAN; BLOOD CLOTTING FACTOR 10A; PLACEBO;

ADULT; AREA UNDER THE CURVE; ARTICLE; BLOOD CLOTTING; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG ACCUMULATION; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DOSE INCREASE; DRUG DOSE SEQUENCE; DRUG HALF LIFE; DRUG SAFETY; DRUG TOLERABILITY; DRUG URINE LEVEL; HUMAN; HUMAN EXPERIMENT; HYPERTRIGLYCERIDEMIA; JAPANESE (PEOPLE); KIDNEY CLEARANCE; LIMB PAIN; MALE; MAXIMUM PLASMA CONCENTRATION; MORNING DOSAGE; MULTIPLE DRUG DOSE; NORMAL HUMAN; PARTIAL THROMBOPLASTIN TIME; PHARMACODYNAMICS; PHARMACOKINETICS; PROTHROMBIN TIME; RANDOMIZED CONTROLLED TRIAL; SINGLE DRUG DOSE; TIME TO MAXIMUM PLASMA CONCENTRATION; TREATMENT DURATION;

ADULT; DOUBLE-BLIND METHOD; FACTOR XA; HUMANS; MALE; PROTHROMBIN TIME; PYRAZOLES; PYRIDONES;

EID: 84904013662     PISSN: 09461965     EISSN: None     Source Type: Journal    
DOI: 10.5414/CP201967     Document Type: Article

References (22)

1. Liew NC, Chans YH, Choi G, Chu PH, Gao X, Gibbs H, Ho CO, Ibrahim H, Kim TK, Kritpracha B, Lee LH, Lee L, Lee WY, Li YJ, Nicolaides AN, Oh D, Pratama D, Ramakrishnan N, Robless PA, Villarama- Alemany G, et al. Asian Venous Thrombosis Forum. Asian venous thromboembolism guidelines: prevention of venous thromboembolism. Int Angiol. 2012; 31; 501-516. PubMed.
2. Toyoda K, Yasaka M. Iwade K, Nagata K. Koretsune Y. Sakamoto T, Uchiyama S, Gotoh J, Nagao T. Yamamoto M, Takahashi JC, Minematsu K; Bleeding with Antithrombotic Therapy (BAT) Study Group. Dual antithrombotic therapy increases severe bleeding events in patients with stroke and cardiovascular disease: A prospective, multicenter, observational study. Stroke. 2008; 39: 1740-1745. CrossRef PubMed.
3. Connolly SJ, Eikelboom J, Joyner C, Diener HC, Hart R, CoHtsyn S, Flaker G, Avezum A, Holm-Loser SH, Diaz R, Talajic M, Zhu J, Pais P, Budaj A, Parkhomenko A, Jansky P, Commerford P, Tan RS, Sim KH, Lewis BS et al.; AVERROESSteering Committee and Investigators. Apixaban in patients with atrial fibrillation. N Engl J Med. 2011; 364: 806-817. CrossRef PubMed.
4. Granger CB, Alexander JH, McMurray JJ, Lopes RD, Hylek EM, Hanna M, Al-Khalidi HR, Ansell J, Atar D, Avezum A, Bahit MC, Diaz R, Easton JD, Ezekowitz J A, Flaker G, Garcia D, Geraldes M, Gersh BJ, Golitsyn S, Goto S, et al. ARISTOTLE Committees and Investigators. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2011; 365: 981-992. CrossRef PubMed.
5. Lassen MR, Raskob GE, Gallus A, Pineo G, Chen D, Hornick P: ADVANCE-2 investigators. Apixa- ban versus enoxaparin for thromboprophylaxis after knee replacement (ADVANCE-2): A randomised double-blind trial. Lancet. 2010; 375: 807-815. CrossRef PubMed.
6. Lassen MR, Gallus A, Raskob GE, Pineo G, Chen D, Ramirez LM; ADVANCE-3 Investigators. Apixaban versus enoxaparin for thromboprophylaxis after hip replacement. N Engl J Med. 2010; 363: 2487-2498. CrossRef PubMed.
7. Agnelli G, Buller HR, Cohen A, Curto M, Gallus AS, Johnson M, Poreari A, Raskob GE, Weitz JI; AMPLIFY-EXT Investigators. Apixaban for extended treatment of venous thromboembolism. N Engl J Med. 2013; 368: 699-708. CrossRef PubMed.
8. Buller H, Deitchman D, Prins M, Segers A; Botticelli Investigators, Writing Committee. Efficacy and safety of the oral direct factor Xa inhibitor apixaban for symptomatic deep vein thrombosis. The Botticelli DVT dose-ranging study. J Ihromb Haemost. 2008; 6: 1313-1318. CrossRef PubMed. (Pubitemid 352016310)
9. Pursley J, Shen JX, Schuster A, Dang OT, Lehman J, Buonarati MH, Song Y, Auhry A-F, Arnold ME. LC-MS/MS determination of apixaban (BMS- 562247) and its major metabolite in human plas-ma - An application of polarity switching and monolithic HPLC column. Bioanalysis. (Accepted for publication August 2014).
10. Perrier D, Gihaldi M. General derivation of the equation for time to reach a certain fraction of steady state. J Pharm Sci. 1982; 71: 474-475. CrossRef PubMed.
11. Barrett YC, Wang Z, Knahh RM. A novel prothrombin time assay for assessing the anticoagu-lant activity of oral factor Xa inhibitors. Clin Appl Thromb Hemost. 2013; 19: 522-528. CrossRef PubMed.
12. Barrett YC, Hang Z, Frost C, Shenker A. Clinical laboratory measurement of direct factor Xa in-hibitors: Anti-Xa assay is preferable to prothrombin time assay. Thromb Haemost 2010; 104: 1263-1271. CrossRef PubMed.
13. Frost C, Nepal S, Hang J, Schuster A, Byon W, Boyd RA, Yu Z, Shenker A, Barrett YC, Mosqueda-Garcia R, Lacreta F. Safety, pharmacokinetics and pharmacodynamics of multiple oral doses of apixaban. a factor Xa inhibitor, in healthy subjects. Br J Clin Pharmacol. 2013: 76: 776-786. CrossRef PubMed.
14. Chen ML. Ethnic or racial differences revisited: impact of dosage regimen and dosage form on pharmacokinetics and pharmacodynamics. Clin Pharmacokinet. 2006; 45: 957-964. CrossRef PubMed.
15. Xie HG, Kim RB, Wood AJ, Stein CM. Molecular basis of ethnic differences in drug disposition and response. Annu Rev Pharmacol Toxicol. 2001; 41: 815-850. CrossRef PubMed. (Pubitemid 32385908)
16. Kim K, Johnson J A, Derendorf H. Differences in drug pharmacokinetics between East Asians and Caucasians and the role of genetic polymorphisms. J Clin Pharmacol. 2004; 44: 1083-1105. CrossRef PubMed. (Pubitemid 39202454)
17. Lai Y, Varma M, Feng B, Stephens JC, Kimoto E, El-Kattan A, Ichikawa K, Kikkawa H, Ono C, Suzuki A, Suzuki M, Yamamoto Y, Tremaine L. Impact of drug transporter pharmacogenomics on pharmacokinetic and pharmacodynamic variability - considerations for drug development. Expert Opin Drug Metab Toxicol. 2012; 8: 723-743. CrossRef PubMed.
18. Frost C, Yu Z, Nepal S, et al. Apixaban, a direct factor Xa inhibitor: single-dose pharmacokinetics and pharmacodynamics of an intravenous formulation [abstract 148], J Clin Pharmacol. 2008; 48: 1132.
19. Vakkalagadda B, Frost C, Wang J, et al. Effect of rifampin on the pharmacokinetics of apixaban, an oral direct inhibitor of factor Xa [abstract]. J Clin Pharmacol. 2009; 49: 1124.
20. Upreti VV, Wang J, Barrett YC, Byon W, Boyd RA, Pursley J, Lacreta FP, Frost CE. Effect of ex- Tremes of body weight on the pharmacokinetics, pharmacodynamics, safety and tolerability of apixaban in healthy subjects. Br J Clin Pharmacol. 2013; 76: 908-916. CrossRef PubMed.
21. Ogawa S, Shinohara Y, Kanmuri K. Safety and efficacy of the oral direct factor Xa inhibitor apixaban in Japanese patients with non-valvular atrial fibrillation. The ARISTOTLE-J study. Circ J. 2011; 75: 1852-1859. CrossRef PubMed.
22. Frost C Wang J, Nepal S, Schuster A, Barrett YC, Mosqueda-Garcia R, Reeves RA, LaCreta F. Apixaban, an oral, direct factor Xa inhibitor: single dose safety, pharmacokinetics, pharmacody-namics and food effect in healthy subjects. Br J Clin Pharmacol. 2013; 75: 476-487. CrossRef PubMed.